Immunogenic Peptide from NGEP Protein for Developing Prostate Cancer Vaccines

The NGEP protein is only present in the prostate and is typically overexpressed on prostate cancer cells. Hence, as a novel prostate tumor-associated antigen (TAA) it is a good target for developing active immunotherapies to kill prostate cancer cells. For example, NGEP could be used in a vaccine to activate an individual's immune system to recognize and kill NGEP-expressing prostate cancer cells. However, TAAs typically are not very effective in inciting an immune response. This can be overcome by identifying portions (epitopes) of the TAA that are more immunologically active.

Investigators at the NIH have identified a small peptide fragment of the NGEP protein (NGEP CTL peptide epitope) that is very effective in activating cytotoxic lymphocytes causing them to destroy prostate cancer cells and has great potential for development of a variety of active immunotherapy strategies, such as vector-based cancer vaccines, to treat and prevent prostate cancer. In addition, it could be used for developing sensitive immunoassays for measuring the immune response of a prostate cancer patient during immunotherapy.

Potential Commercial Applications: Competitive Advantages:
  • Peptide cancer vaccine
  • Vector-based cancer vaccine
  • Liposome-based cancer vaccine
  • Cellular cancer vaccine
  • In vitro diagnostic for monitoring the immune response of prostate cancer patients during cancer vaccine trials
  • Small biologic therapeutic
  • Can be chemically synthesized or produced recombinantly
  • DNA encoded peptide allows molecular engineering
  • Can be used as a tumor antigen with the clinically proven TRICOM-based vaccine technology

Development Stage:
Pre-clinical (in vivo)


Jeffrey Schlom (NCI)  ➽ more inventions...

Ira Pastan (NCI)  ➽ more inventions...

Kwong-Yok Tsang (NCI)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8748390
Foreign Filed Application No. PCT/US10/31584
US Application No. 13/265,490
US Application No. 14/299,763

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-042-2009
Updated: Oct 4, 2017